Repare Therapeutics Inc. (RPTX)
Repare Therapeutics Statistics
Share Statistics
Repare Therapeutics has 42.51M shares outstanding. The number of shares has increased by 0.15% in one year.
| Shares Outstanding | 42.51M |
| Shares Change (YoY) | 0.15% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 72.15% |
| Shares Floating | 30.52M |
| Failed to Deliver (FTD) Shares | 57.3K |
| FTD / Avg. Volume | 23.66% |
Short Selling Information
The latest short interest is 1.06M, so 2.49% of the outstanding shares have been sold short.
| Short Interest | 1.06M |
| Short % of Shares Out | 2.49% |
| Short % of Float | 3.47% |
| Short Ratio (days to cover) | 6.78 |
Valuation Ratios
The PE ratio is -0.66 and the forward PE ratio is -0.85. Repare Therapeutics's PEG ratio is 0.06.
| PE Ratio | -0.66 |
| Forward PE | -0.85 |
| PS Ratio | 1.04 |
| Forward PS | 0.3 |
| PB Ratio | 0.37 |
| P/FCF Ratio | -0.73 |
| PEG Ratio | 0.06 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Repare Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.77, with a Debt / Equity ratio of 0.01.
| Current Ratio | 6.77 |
| Quick Ratio | 6.77 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.03 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $414.55K |
| Profits Per Employee | $-656.5K |
| Employee Count | 129 |
| Asset Turnover | 0.3 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 1.44M |
| Effective Tax Rate | -1.73% |
Stock Price Statistics
The stock price has increased by -66.77% in the last 52 weeks. The beta is 0.91, so Repare Therapeutics's price volatility has been higher than the market average.
| Beta | 0.91 |
| 52-Week Price Change | -66.77% |
| 50-Day Moving Average | 1.13 |
| 200-Day Moving Average | 2.44 |
| Relative Strength Index (RSI) | 55.22 |
| Average Volume (20 Days) | 242.17K |
Income Statement
In the last 12 months, Repare Therapeutics had revenue of 53.48M and earned -84.69M in profits. Earnings per share was -2.
| Revenue | 53.48M |
| Gross Profit | 53.48M |
| Operating Income | -93.52M |
| Net Income | -84.69M |
| EBITDA | -90.22M |
| EBIT | -92.14M |
| Earnings Per Share (EPS) | -2 |
Balance Sheet
The company has 84.72M in cash and 1.93M in debt, giving a net cash position of 82.78M.
| Cash & Cash Equivalents | 84.72M |
| Total Debt | 1.93M |
| Net Cash | 82.78M |
| Retained Earnings | -417.8M |
| Total Assets | 176.51M |
| Working Capital | 145.86M |
Cash Flow
In the last 12 months, operating cash flow was -76.44M and capital expenditures 0, giving a free cash flow of -76.44M.
| Operating Cash Flow | -76.44M |
| Capital Expenditures | 0 |
| Free Cash Flow | -76.44M |
| FCF Per Share | -1.8 |
Margins
Gross margin is 100%, with operating and profit margins of -174.88% and -158.37%.
| Gross Margin | 100% |
| Operating Margin | -174.88% |
| Pretax Margin | -155.67% |
| Profit Margin | -158.37% |
| EBITDA Margin | -168.71% |
| EBIT Margin | -174.88% |
| FCF Margin | -142.95% |
Dividends & Yields
RPTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for RPTX is $4.5, which is 305.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $4.5 |
| Price Target Difference | 305.4% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | -2.81 |
| Piotroski F-Score | 4 |